The Frontier: Current Research and Where This Is Heading
Source: Chapter 5 (deep-verification edition, 13 August 2026), sections 5.1–5.4. The chapter’s Watchlist has been moved to the end of this document as its final content section, per the assembly brief.
Where the field is heading: the active trial landscape, the emerging science, the chronic-CH problem, and the structural funding picture.
Deep-verification edition, compiled 13 August 2026. This supersedes an earlier quick-pass version of this chapter. Four dedicated research passes (global trial-registry sweep, funding/advocacy audit, genetics/imaging/biomarker verification, and psychedelics/PACAP/orexin verification) were run and cross-checked against primary sources. The verification pass found and corrected seven factual errors in the earlier draft — wrong GWAS locus list, wrong odds ratio, an inverted cytokine-direction claim, a misattributed review, and a mislabelled clinical outcome. Corrections are flagged explicitly below rather than silently fixed, in keeping with this document’s evidence standards.
This is not medical advice. It is an independent, privately maintained research summary that is revised continuously and may contain errors, omissions or findings since superseded. Treatment decisions belong with a qualified clinician who knows your history.Read the full notice.
If you are in crisis, please stop reading and reach someone now — thecrisis lines are listed here.